Botensilimab (AGEN 1181) is a humanized monoclonal antibody that specifically targets cytotoxic T-lymphocyte antigen 4 (CTLA-4). Botensilimab (AGEN 1181) functions as a potent activator of both innate and adaptive immune responses. Botensilimab (AGEN 1181) is under active research for its capacity to enhance antitumor immunity and modulate checkpoint pathways.
Purity:
95.00%
CAS Number:
[2408310-37-0]
Target:
Immunology/Inflammation related
* VAT and and shipping costs not included. Errors and price changes excepted